For healthcare professionals only


FDA looks afresh at adulteration of products

BMJ 2009; 338 doi: (Published 06 May 2009) Cite this as: BMJ 2009;338:b1851
  1. Bob Roehr
  1. 1Washington, DC

    The US Food and Drug Administration is hoping to develop new strategies to predict, screen for, and identify economically motivated adulteration of food, supplements, and drugs. The first public meeting in what is likely to become a series of ongoing collaborations took place near Washington, DC, on 1 May.

    Such adulteration was one of the main reasons for the agency’s creation more than a century ago. Concern was revived recently by incidents of melamine in pet food and infant formula and of substitutions in heparin, all of which led to illness and death within the past two years (BMJ 2008;337:a1890, doi:10.1136/bmj.a1890; 2008;336:412-3, doi:10.1136/bmj.39496.419248.DB).

    “The reason this problem has resurged is largely because of globalisation. That is the …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription